Baird lowered the firm’s price target on Dentsply Sirona (XRAY) to $12 from $14 and keeps a Neutral rating on the shares. The firm adjusted ratings and price targets in medical technology as part of its 2026 outlook. Baird sees “several potential paths to improved” share performance for the group in 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XRAY:
- Dentsply Sirona initiated with an Underweight at Barclays
- DENTSPLY SIRONA Appoints Interim CFO Michael Pomeroy
- Dentsply Sirona price target lowered to $14 from $18 at Barrington
- Dentsply Sirona price target lowered to $12 from $14 at Morgan Stanley
- Dentsply Sirona price target lowered to $13 from $16 at Mizuho